Takeda Pharmaceutical Co. Ltd.
Rank 15 in 2016
Rises further than all other companies, moving 10 places to 5th. Takeda has newly assigned responsibility for access to its CEO, with a raft of new policies, deepening its approach to equitable pricing, with a solid approach to Capacity Building.
Rises 10 places, to 6th place with responsibility for the company’s access-to-health strategy newly assigned to the CEO. It demonstrates innovation with the development of the Cancer Alliance.
Rises 7 places to 6th place as its code of conduct applies to third parties, rewards for sales agents are not solely based on sales.
Rises 1 place to 6th with a solid performance, but displaced by peers due to lagging slightly behind in priority R&D and access planning.
Rising 11 places to 5th; it has a large increase of products with equitable pricing strategies.
Rises 11 places to 6th, a leading company in IP-sharing, along with a new public commitment not to enforce patents in LDCs and new levels of patent disclosure.
Rises 3 places to 7th. Deepened approach to capacity building with a focus on strengthening health systems.
Rises 2 places to 14th, with no structured donation programmes, but working with partners to ensure rapid delivery of products in emergencies and humanitarian crises.
Expand price segmentation approach. Takeda developed a sophisticated Patient Assistance Tool to define intra-country pricing segmentation for some countries in scope. The company could apply this tool to more of its marketed products, for example, leuprorelin acetate (Enantone®) and leuprorelin (Lupron), both 2017 WHO Model List of Essential Medicines (WHO EML) listed cancer products in the scope of the Index, in countries where the tool is already being applied for other products, and to more countries in scope.
Establish project-specific access plans for late-stage projects, particularly for non-communicable diseases. Takeda can establish project-specific access plans for all late-stage projects with a focus on its non-communicable disease projects, such as those targeting cancer. By ensuring that access plans are not only considered but established, it can address key barriers to access that normally restrict access in low- and middle-income countries.
Strengthen registration approach. Takeda has registered aloglitpin (Nesina®) for diabetes mellitus in five out of twelve possible priority countries. The company could file to register the product in more priority countries, for example, Afghanistan, Dem. Rep. Congo, Ethiopia, Tanzania and Uganda.
Strengthen commitments through transparency to public. Takeda has strong, clear commitments to conduct R&D for diseases and countries in scope and for providing post-trial access to clinical trial participants. However, these policies are not readily available. Takeda can publish these commitments, reinforcing its values to advance access to medicine through R&D.
Change since 2016
- Established a structured process to develop access provisions for R&D projects, with execution carried out by a designated R&D Access to Medicine Office.
- Joined Access Accelerated with multiple initiatives, most focused on cancer care. It has also committed to measure impact and share results publicly via Access Observatory.
- Launched its Chronic Care Program in late 2016, focused on improving public awareness and equipping community and primary healthcare workers for detecting diseases such as diabetes and hypertension.
- Launched the Strengthening Health Systems through Technology in 2017 which focuses on introducing and adopting digital platforms to strengthen healthcare delivery and management in low- and middle-income countries.
- Commits to file submissions globally for the registration of all new products in parallel to major markets.
- Publicly discloses its new commitments to either not file or not enforce patents for its medicines in Least Developed Countries.
- Discloses publicly the patent statuses for small molecules in scope via the Pat-INFORMED platform
Pipeline and Portfolio
for diseases and countries in scope
Mid-sized pipeline: 35 R&D projects for diseases in scope (30 medicines; 5 preventive vaccines).
Clinical candidates: 27, including preventive vaccines for Zika virus, norovirus and dengue.
Regulatory approvals: 1, brigatinib (Alunbrig™) for the treatment of metastatic lung cancer.
R&D focus: non-communicable diseases (cancer and schizophrenia) and communicable diseases (malaria).
Access provisions: for 10 projects, most commonly applied through access-oriented partnerships.
Mid-sized portfolio: 42 products for diseases in scope (all medicines).
Portfolio focus: non-communicable diseases (hypertensive heart disease and diabetes mellitus) and communicable diseases (lower respiratory infections).
Essential medicines: 52% of Takeda's medicines are currently listed on the 2017 WHO Model List of Essential Medicines (WHO EML).
First-line treatments: 48% of Takeda's medicines have first-line indications for diseases in scope.
Six business units: Four geographic business units - Emerging Markets, Europe & Canada, Japan, and the US; two therapeutic area business units - Oncology and Vaccines. Its portfolio of prescription drugs focus on: oncology; gastroenterology; neuroscience disorders; and vaccines.
M&A news: 2017 divestment of respiratory business to AstraZeneca; acquisition of oncology company ARIAD Pharmaceuticals. 2018 ongoing acquisition (expected to conclude mid-2019) of Shire, a biotechnology company specialising in rare diseases.
Presence in emerging markets: In 2018, Takeda reports sales in 44 countries in scope; five more than in the 2016 Index.
*Neglected Tropical Diseases, while also communicable, are highlighted separately throughout the Index. See Appendix II.
**See Appendix IV for definition.